Please login to the form below

Not currently logged in
Email:
Password:

R&D news in brief

Our weekly round up of R&D news in brief

New ADHD drug edges closer to launch

US company Cephalon says it has received an approvable letter from the US Food and Drug Administration for a new drug to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents. The drug, which would be sold in the US under the brand name Sparlon, would be co-marketed with a unit of Johnson & Johnson. Dr Chris Kratochvil, an associate psychiatry professor at the University of Nebraska Medical Centre said that although other ADHD drugs such as Novartis' Ritalin and Shire's Adderall were effective overall, doctors needed additional options because not all drugs were effective in individual patients.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics